For research use only. Not for therapeutic Use.
Lacosamide acts by enhancing slow inactivation of voltage gated sodium channels; a medication for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain
| Catalog Number | I047539 |
| CAS Number | 175481-36-4 |
| Molecular Formula | C13H18N2O3 |
| Purity | ≥95% |
| IUPAC Name | (2R)-2-acetamido-N-benzyl-3-methoxypropanamide |
| InChI | InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1 |
| SMILES | CC(=O)N[C@H](COC)C(=O)NCC1=CC=CC=C1 |
| Reference | AC Errington et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Molecular pharmacology 2008, 73 (1), 157–69.
AC Errington et al. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology 2006, 50 (8), 1016–1029.
E Ben-Menachem et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007, 48 (7), 1308–1317.
RL Rauck et al. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain 2007, 23 (2), 150–158.
PL Sheets et al. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J Pharmacol Exp Ther. 2008 Jul;326(1):89-99. |
